Navigation Links
Fetal Exposure to Common Epilepsy Drugs May Harm Kids' IQ: FDA
Date:6/30/2011

THURSDAY, June 30 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday advised doctors to warn women of childbearing age that fetal exposure to certain drugs used to control seizures or migraines appears to diminish intellectual abilities in offspring.

The drugs include so-called "valproate products" -- medications such as valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, Depakote ER), valproic acid (Depakene, Stavzor), and their equivalent generic formulations, the FDA said in a statement.

Children born to women who take these medications during their pregnancy "have an increased risk of lower cognitive test scores than children exposed to other anti-seizure medications during pregnancy," the FDA said.

The agency said it based its conclusions on epidemiological studies that showed that fetal exposures to the drugs tended to correlate with lower scores on IQ and other cognitive tests.

Valproate drugs are FDA-approved for use against epilepsy, migraine and bipolar disorder, although the agency notes that they are also used "off-label" for other conditions, mainly other psychiatric disorders.

The drugs have also long been linked to an increased risk of birth defects known as neural tube defects, the agency noted.

The FDA advises that doctors counsel women of childbearing age of the risks to offspring associated with valproate products, and "weigh the benefits and risks of valproate when prescribing this drug to women of childbearing age, particularly when treating a condition not usually associated with permanent injury or death. Alternative medications that have a lower risk of adverse birth outcomes should be considered."

In late 2010, a Swedish study of over 1,200 teenage children born to women with epilepsy found that those born to women who took two or more epilepsy drugs while pregnant fared worse in school than peers with no prenatal exposure to those medications.

The findings, published in Epilepsia, echoed earlier research that linked prenatal exposure to epilepsy drugs, particularly valproic acid medications (such as Depakene and Depakote), to negative effects on a child's ability to process information, solve problems and make decisions.

"Our results suggest that exposure to several anti-epileptic drugs in utero may have a negative effect on a child's neurodevelopment," study author Dr. Lisa Forsberg of Karolinska University Hospital told HealthDay at the time.

Forsberg recommended that women with epilepsy plan their pregnancies. "That way, they and their doctors can come up with individual treatment plans that make the pregnancy safe for both mother and child," she said.

More information

To learn more about women and epilepsy, visit the Epilepsy Foundation.

-- HealthDay Staff

SOURCES: Lisa Forsberg, M.D., Karolinska University Hospital, Stockholm, Sweden; U.S. Food and Drug Administration, news release, June 30, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Ultrasensitive detector pinpoints big problem in tiny fetal heart
2. Fetal alcohol spectrum disorder linked to high prevalence of epilepsy, Queens study
3. Study finds changes in fetal epigenetics throughout pregnancy
4. Hurricanes Linked to Raised Fetal Distress Risk
5. AIUM announces ultrasound practice accreditation in fetal echocardiography
6. Figuring out fetal alcohol syndrome in fruit flies
7. Fetal Surgery Could Boost Outcomes in Severe Spina Bifida
8. Study finds even with fetal lung maturity, babies delivered prior to 39 weeks are at risk
9. Study finds that electronic fetal heart rate monitoring greatly reduces infant mortality
10. Society for Maternal-Fetal Medicine commends FDA on makena announcement
11. The TET1 enzyme steers us through fetal development and fights cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fetal Exposure to Common Epilepsy Drugs May Harm Kids' IQ: FDA
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology: